Over the last three decades, our understanding of cancer genetic susceptibility syndromes has increased dramatically. The identification of these syndromes has provided insights into cancer biology and informed approaches to patient care. This session will discuss cancer genetic susceptibility syndromes, with an emphasis on those that predispose to leukemia. We will also discuss the ways in which germline genetic information can be used to enhance the management of patients with leukemia and their families.
Dr. Kim Nichols will provide an overview of hereditary predisposition to cancer. She will review the factors that should trigger consideration of an underlying cancer predisposition syndrome and discuss how germline genetic information can influence cancer management, surveillance and/or prevention.
Dr. Christopher Porter will discuss genetic susceptibility to myeloid and lymphoid leukemias. He will describe syndromic and non-syndromic disorders, review the genes involved in these conditions, and discuss the underlying biology of these syndromes.
Dr. Joshua Schiffman will review the clinical challenges and uncertainties associated with genetic testing for heritable predisposition to leukemia. These challenges range from how to best interpret, communicate and act upon germline genetic variants and mutations.
Kim E. Nichols, MD
Christopher C. Porter, MD
Joshua Schiffman, MD
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members